Tungsten West — Financial Results for the Year Ended 31 March 2026

Tungsten West secures full funding, narrows losses, and begins initial production at Hemerdon.

What the company is saying

Tungsten West frames the year as a turning point, highlighting a strong safety record with zero Lost Time Incidents during a major ramp-up at Hemerdon. The company stresses its successful £43 million equity raise in February 2026 and a further commitment of up to £71 million from the UK Government's National Wealth Fund in August, asserting that it is now fully funded through to full production. Management claims significant progress, with initial tungsten and tin concentrate production already underway and full commissioning targeted for Q1 2027. The narrative emphasises improved project economics due to tighter global tungsten supply following Chinese export controls, though no specific price data is provided. Leadership appointments and a growing workforce of over 150 employees are presented as evidence of operational readiness. The company repeatedly states that a large £167.3 million non-cash finance adjustment from convertible loan conversions had no impact on liquidity, aiming to reassure investors about the underlying financial health.

What the data suggests

The company reported revenue of £601,550 for the year ended 31 March 2026, with first tungsten concentrate sales of £0.6 million in December 2025. Cost of sales was £152,053, resulting in a gross profit of £449,497. Administrative expenses totaled £8,809,815, and other operating income was £420,000. The operating loss narrowed sharply to £7.9 million from £19 million in 2025, reflecting reduced pre-operational costs and the transition to initial production. The total comprehensive loss was £175,446,271, driven by a £167.3 million non-cash finance adjustment related to convertible loan note conversions, which management states did not affect cash. Cash and cash equivalents rose to £25,485,511 at year-end, up from £20,000 the prior year, due to £43 million in equity raised and other financing activities. The company secured additional post-year-end funding: a £36 million equity raise, a £25 million loan facility, and a £10 million accordion from the National Wealth Fund. Over 150 employees have been hired to support the restart. The company is in the construction and commissioning phase, with full production targeted by the end of Q1 2027. No detailed production volumes or updated project economics are disclosed, and realised sales remain modest relative to capital invested.

Analysis

The announcement is upbeat, highlighting successful fundraising, improved cash position, and the transition from pre-revenue to initial sales. However, the majority of the positive narrative is anchored in forward-looking statements about completing construction and ramping up to full production by Q1 2027, with only modest realised revenue (£0.6m in concentrate sales, £601k total revenue) and a substantial operating loss (£7.9m). The capital intensity is high, with over £100m in new funding (equity and government investment) committed to a project that is not yet fully operational. While the company has executed key contracts and begun initial production, the scale of realised commercial activity is still limited relative to the capital deployed. The tone is somewhat inflated by references to 'significantly improved project economics' and market strength without supporting numerical evidence. The data supports a weak_positive signal due to clear progress and full financial disclosure, but the gap between narrative and realised operational performance is material.

Risk flags

• ●Execution risk is high: The company is still in the construction and commissioning phase, with full production not expected until Q1 2027. Delays, cost overruns, or technical issues could materially impact the timeline and financial outcomes.
• ●Capital intensity is significant: Over £100 million in new funding has been committed, but realised revenue remains low (£601,550 for the year). Sustained losses are likely until commercial production is achieved, and further capital may be needed if ramp-up is slower than planned.
• ●Market risk persists: The company cites stronger tungsten prices due to Chinese export controls, but provides no specific market data or offtake agreements. If prices weaken or sales volumes disappoint, project economics could deteriorate.
• ●Disclosure risk: While financial data is comprehensive, the absence of detailed production volumes, sales contracts, or updated project economics limits visibility into operational performance and future cash flow potential.

Bottom line

Tungsten West has secured substantial funding, narrowed its operating loss to £7.9 million, and begun initial concentrate production at Hemerdon, but remains pre-commercial with only £601,550 in revenue for the year. The company is fully funded through to targeted full production in Q1 2027, following a £43 million equity raise and up to £71 million from the UK Government's National Wealth Fund. The £167.3 million non-cash finance adjustment inflates the reported loss but does not affect cash or liquidity. Execution risk is elevated, as the project is still in ramp-up and has yet to demonstrate sustained commercial output or profitability. Investors should focus on evidence of successful commissioning, material sales volumes, and updated project economics in future disclosures. The main takeaway: Tungsten West is well-capitalised and progressing, but the transition to meaningful cash flow and operational de-risking is still several quarters away.

Announcement summary

(LON:TUN) Tungsten West Plc reported audited financial results for the year ended 31 March 2026, highlighting a strong safety record with zero Lost Time Incidents as the Hemerdon Project ramped up construction and operational readiness. The company raised £43 million (gross) in equity funds in February 2026, enabling the commencement of construction and advancing the timeline to production. Year-end cash and cash equivalents increased substantially to £25.5 million from £0.02 million in 2025, primarily due to funding activities. Tungsten West recorded its first tungsten concentrate sales of £0.6 million in December 2025 from the re-commissioned Mineral Processing Facility. The company executed major equipment supply contracts, including an EPC contract with Duo Group, a supply agreement with Gekko Systems Pty Limited, and an equipment supply contract with McHale Komatsu. The company commenced operation of the fines gravity circuit and produced tungsten and tin concentrate as part of its restart plans. In August 2026, Tungsten West announced an investment of up to £71 million from the UK Government's National Wealth Fund, ensuring full funding through to full production. For the year ended 31 March 2026, the company reported an operating loss of £7.9 million (2025: operating loss of £19 million), reflecting key initiatives such as finalising the feasibility study and pre-operational readiness. Multiple fundraising transactions were completed, including £5.2 million from Convertible Loan Notes, £4.0 million committed under a bridge finance facility, and the conversion of CLNs into equity, resulting in a non-cash finance adjustment of £167.3 million. The company is on track to complete restart construction activities on time and within budget by the end of Q1 2027, with initial production already underway in Q3 2026. The company reported a total comprehensive loss of £175,446,271 for the year. Over 150 employees have joined to support the restart, with further recruitment planned as operations expand. China's introduction of tungsten export controls in February 2025 tightened supply outside China, contributing to stronger tungsten prices and improved project economics.

Disagree with this article?